PTC Therapeutics logo

PTC Therapeutics Stock

StockStock
ISIN: US69366J2006
Ticker: PTCT
US69366J2006
PTCT

Price

Frequently asked questions

What is PTC Therapeutics's market capitalization?

The market capitalization of PTC Therapeutics is $3.46B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for PTC Therapeutics?

PTC Therapeutics's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$5.94. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for PTC Therapeutics's stock?

Currently, 13 analysts cover PTC Therapeutics's stock, with a consensus target price of $36.82. Analyst ratings provide insights into the stock's expected performance.

What is PTC Therapeutics's revenue over the trailing twelve months?

Over the trailing twelve months, PTC Therapeutics reported a revenue of $900.66M.

What is the EBITDA for PTC Therapeutics?

PTC Therapeutics's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $21.05M. EBITDA measures the company's overall financial performance.

What is the free cash flow of PTC Therapeutics?

PTC Therapeutics has a free cash flow of -$186.27M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of PTC Therapeutics's stock?

The 5-year beta for PTC Therapeutics is 0.63. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does PTC Therapeutics have, and what sector and industry does it belong to?

PTC Therapeutics employs approximately 988 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of PTC Therapeutics's shares?

The free float of PTC Therapeutics is 75.32M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 
$3.46B

5Y beta

 
0.63

EPS (TTM)

 
-$5.94

Free Float

 
75.32M

Revenue (TTM)

 
$900.66M

EBITDA (TTM)

 
$21.05M

Free Cashflow (TTM)

 
-$186.27M

Pricing

1D span
$43.56$45.16
52W span
$19.75$46.98

Analyst Ratings

The price target is $36.82 and the stock is covered by 13 analysts.

Buy

5

Hold

4

Sell

4

Information

PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

988

Biotechnology & Drugs

Health Care

Identifier

ISIN

US69366J2006

Primary Ticker

PTCT

Knockouts

Join the conversation